PMID- 33971788
OWN - NLM
STAT- MEDLINE
DCOM- 20220421
LR  - 20220430
IS  - 1744-8336 (Electronic)
IS  - 1478-7210 (Linking)
VI  - 20
IP  - 1
DP  - 2022 Jan
TI  - Clinical efficacy and safety of ceftobiprole in the treatment of acute bacterial 
      skin and skin structure infection: a systematic review and meta-analysis of 
      randomized controlled trials.
PG  - 95-102
LID - 10.1080/14787210.2021.1927711 [doi]
AB  - OBJECTIVES: To investigate the clinical efficacy and safety of ceftobiprole for 
      acute bacterial skin and skin structure infections (ABSSSIs). METHODS: PubMed, 
      Web of Science, EBSO, Ovid Medline, ClinicalTrial.gov and Cochrane Library were 
      searched until 25 December 2020. Only randomized controlled trials that compared 
      the treatment efficacy of ceftobiprole with that of other antibiotics for adult 
      patients with ABSSSIs were included in this meta-analysis. RESULTS: The 3 RCTs 
      involving 2291 adult patients with ABSSSIs were included. No significant 
      difference in clinical success, as measured by the TOC, was observed between 
      ceftobiprole and comparators among the intention-to-treat population (OR, 1.06; 
      95% CI, 0.85-1.33; I(2) = 0%) and clinical evaluable population (OR, 1.17; 95% 
      CI, 0.76-1.79; I(2) = 17%). Ceftobiprole was associated with a similar risk of 
      adverse events (AEs) to that of comparators. CONCLUSIONS: Ceftobiprole can 
      achieve similar clinical and microbiological responses as alternative antibiotics 
      in patients with ABSSSIs. In addition, ceftobiprole shares a similar safety 
      profile to comparators.
FAU - Lan, Shao-Huan
AU  - Lan SH
AD  - School of Pharmaceutical Sciences and Medical Technology, Putian University, 
      Putian China.
FAU - Lee, Hong-Zin
AU  - Lee HZ
AD  - School of Pharmacy, China Medical University, Taichung, Taiwan.
FAU - Lai, Chih-Cheng
AU  - Lai CC
AD  - Department of Internal Medicine, Kaohsiung Veterans General Hospital, Tainan, 
      Taiwan.
FAU - Chang, Shen-Peng
AU  - Chang SP
AD  - Yijia Pharmacy, Tainan Taiwan.
FAU - Lu, Li-Chin
AU  - Lu LC
AD  - School of Management, Putian University, Putian China.
FAU - Hung, Shun-Hsing
AU  - Hung SH
AD  - Division of Urology, Department of Surgery, Chi-Mei Hospital, Tainan, Taiwan.
FAU - Lin, Wei-Ting
AU  - Lin WT
AD  - Department of Orthopedic, Chi Mei Medical Center, Tainan Taiwan.
AD  - Department of Mechanical Engineering, Southern Taiwan University of Science and 
      Technology, Tainan, Taiwan.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20210615
PL  - England
TA  - Expert Rev Anti Infect Ther
JT  - Expert review of anti-infective therapy
JID - 101181284
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Cephalosporins)
RN  - 5T97333YZK (ceftobiprole)
SB  - IM
MH  - Adult
MH  - Anti-Bacterial Agents/adverse effects
MH  - *Cephalosporins/adverse effects
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - *Skin Diseases, Infectious/drug therapy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - *Skin and skin structure infection
OT  - *ceftobiprole
OT  - *mortality
OT  - *vancomycin
EDAT- 2021/05/12 06:00
MHDA- 2022/04/22 06:00
CRDT- 2021/05/11 05:33
PHST- 2021/05/12 06:00 [pubmed]
PHST- 2022/04/22 06:00 [medline]
PHST- 2021/05/11 05:33 [entrez]
AID - 10.1080/14787210.2021.1927711 [doi]
PST - ppublish
SO  - Expert Rev Anti Infect Ther. 2022 Jan;20(1):95-102. doi: 
      10.1080/14787210.2021.1927711. Epub 2021 Jun 15.